NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $466,283 | +44.8% | 28,872 | +272.1% | 0.00% | 0.0% |
Q2 2023 | $322,041 | -62.5% | 7,760 | -45.7% | 0.00% | -50.0% |
Q1 2023 | $858,979 | +72756.6% | 14,283 | -11.1% | 0.00% | -33.3% |
Q4 2022 | $1,179 | -99.9% | 16,061 | +1.5% | 0.00% | -25.0% |
Q3 2022 | $1,203,000 | +10.0% | 15,831 | +0.5% | 0.00% | +33.3% |
Q2 2022 | $1,094,000 | -4.0% | 15,746 | +82.7% | 0.00% | 0.0% |
Q1 2021 | $1,139,000 | -4.6% | 8,619 | +24.9% | 0.00% | -25.0% |
Q4 2020 | $1,194,000 | +37.7% | 6,899 | -11.4% | 0.00% | +33.3% |
Q3 2020 | $867,000 | +238.7% | 7,787 | +80.4% | 0.00% | +200.0% |
Q2 2020 | $256,000 | -2.3% | 4,316 | +10.9% | 0.00% | 0.0% |
Q1 2020 | $262,000 | +21.9% | 3,891 | +52.8% | 0.00% | 0.0% |
Q4 2019 | $215,000 | -14.7% | 2,546 | -24.5% | 0.00% | 0.0% |
Q3 2019 | $252,000 | – | 3,373 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |